logo-loader
viewNeuroDerm

NeuroDerm to present trial data at Parkinson’s conference

It will be presented at the 20th International Congress on Parkinson’s Disease and Movement Disorders

rsz_shutterstock_215666209.jpg
The company will release data on its ND0612H for the treatment of Parkinson’s diseases.

NeuroDerm Ltd (NASDAQ:NDRM), is to present the design and data of its ongoing Phase II clinical trial of ND0612H for the treatment of Parkinson’s diseases.

It will be presented at the 20th International Congress on Parkinson’s Disease and Movement Disorders taking place June 19 to June 23, 2016 in Berlin, Germany.  

ND0612H’s first efficacy trial started in December 2015 and is a multicenter, open-label, rater-blind Phase II study.

In all, the trial, designed to investigate the safety and tolerability, will enroll 36 Parkinson's disease patients whose symptoms are not adequately controlled with oral medications.  

The clinical-stage pharma company developing drugs for central nervous system (CNS) diseases, will also announce pre-clinical data investigating ND0701, its new product candidate for the treatment of Parkinson’s disease.

Quick facts: NeuroDerm

Price: - -

NASDAQ:NDRM
Market: NASDAQ
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Tocvan preparing for a busy 2020 on a project in Mexico with...

Tocvan (CSE: TOC) Director Brodie Sutherland joined Steve Darling in the Vancouver studio of Proactive to discuss the company’s Mexican asset. Sutherland talked about the history of the project and the advantages they have because of the location.  Sutherland also told Proactive what...

8 hours, 17 minutes ago

2 min read